2024 Q2 Form 10-Q Financial Statement
#000149315224019364 Filed on May 15, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $1.298M | $1.934M | $2.784M |
| YoY Change | -58.88% | -30.55% | 0.59% |
| % of Gross Profit | |||
| Research & Development | $515.5K | $458.2K | $1.990M |
| YoY Change | -79.49% | -76.98% | 1.6% |
| % of Gross Profit | |||
| Depreciation & Amortization | $42.59K | $43.22K | $44.30K |
| YoY Change | -3.93% | -2.43% | -36.05% |
| % of Gross Profit | |||
| Operating Expenses | $515.5K | $458.2K | $1.990M |
| YoY Change | -79.49% | -76.98% | -58.51% |
| Operating Profit | -$1.898M | -$2.477M | -$4.861M |
| YoY Change | -67.02% | -49.03% | 1.35% |
| Interest Expense | $7.730K | $12.09K | $11.00 |
| YoY Change | -102.1% | 109809.09% | -100.27% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $18.54K | $22.13K | $183.2K |
| YoY Change | -103.08% | -87.92% | -33.63% |
| Pretax Income | -$1.879M | -$2.455M | -$4.678M |
| YoY Change | -70.43% | -47.51% | 3.39% |
| Income Tax | $1.731K | ||
| % Of Pretax Income | |||
| Net Earnings | -$1.879M | -$2.457M | -$4.678M |
| YoY Change | -70.43% | -47.47% | 3.39% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | -$0.25 | -$0.61 | -$2.31 |
| Diluted Earnings Per Share | -$0.25 | -$0.61 | -$2.31 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 7.752M shares | 7.294M shares | 2.078M shares |
| Diluted Shares Outstanding | 7.588M shares | 4.001M shares | 2.078M shares |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $3.503M | $6.356M | $12.56M |
| YoY Change | -50.54% | -49.4% | -42.1% |
| Cash & Equivalents | $3.503M | $6.356M | $12.56M |
| Short-Term Investments | |||
| Other Short-Term Assets | $1.718M | $1.417M | $2.277M |
| YoY Change | -5.53% | -37.77% | 134.54% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $5.520M | $8.229M | $14.84M |
| YoY Change | -37.98% | -44.55% | -34.53% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $405.1K | $452.2K | $638.9K |
| YoY Change | -31.94% | -29.22% | -31.16% |
| Goodwill | $337.5K | ||
| YoY Change | |||
| Intangibles | $168.7K | ||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | |||
| YoY Change | |||
| Total Long-Term Assets | $531.7K | $621.0K | $1.013M |
| YoY Change | -40.94% | -38.73% | -89.35% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $5.520M | $8.229M | $14.84M |
| Total Long-Term Assets | $531.7K | $621.0K | $1.013M |
| Total Assets | $6.052M | $8.850M | $15.85M |
| YoY Change | -38.25% | -44.17% | -50.74% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $459.9K | $1.853M | $1.793M |
| YoY Change | -62.75% | 3.34% | 47.17% |
| Accrued Expenses | $176.4K | $487.5K | $1.028M |
| YoY Change | -88.24% | -52.59% | 17.48% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $645.3K | $2.368M | $4.438M |
| YoY Change | -86.9% | -46.65% | 112.0% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $645.3K | $2.368M | $4.438M |
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $645.3K | $2.368M | $5.447M |
| YoY Change | -86.9% | -56.52% | -29.61% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$100.8M | -$98.96M | -$83.89M |
| YoY Change | 11.74% | 17.97% | |
| Common Stock | $78.79K | $72.94K | $20.78K |
| YoY Change | 267.86% | 250.97% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $5.406M | $6.482M | $10.41M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $6.052M | $8.850M | $15.85M |
| YoY Change | -38.25% | -44.17% | -50.74% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$1.879M | -$2.457M | -$4.678M |
| YoY Change | -70.43% | -47.47% | 3.39% |
| Depreciation, Depletion And Amortization | $42.59K | $43.22K | $44.30K |
| YoY Change | -3.93% | -2.43% | -36.05% |
| Cash From Operating Activities | -$2.889M | -$2.598M | -$5.137M |
| YoY Change | -35.31% | -49.42% | 12.93% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $0.00 | $5.169K | |
| YoY Change | -100.0% | -101.02% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $4.495M | -$4.495M | |
| YoY Change | 26542.68% | ||
| Cash From Investing Activities | $0.00 | -$5.169K | |
| YoY Change | -100.0% | -98.98% | |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 34.43K | $6.658M | |
| YoY Change | -103.27% | ||
| NET CHANGE | |||
| Cash From Operating Activities | -2.889M | -$2.598M | -$5.137M |
| Cash From Investing Activities | 0.000 | -$5.169K | |
| Cash From Financing Activities | 34.43K | $6.658M | |
| Net Change In Cash | -2.855M | $4.068M | -$5.162M |
| YoY Change | -48.11% | -178.81% | -218.85% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$2.889M | -$2.598M | -$5.137M |
| Capital Expenditures | $0.00 | $5.169K | |
| Free Cash Flow | -$2.889M | -$2.598M | -$5.142M |
| YoY Change | -35.31% | -49.47% | 27.17% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
usd | |
| CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
usd | |
| CY2024Q1 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
usd | |
| CY2024Q1 | us-gaap |
Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
|
usd | |
| CY2024Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
usd | |
| CY2024Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
usd | |
| CY2024Q1 | ENVB |
Increase Decrease In Rightofuse Operating Lease Asset And Obligation
IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation
|
usd | |
| CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
usd | |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
usd | |
| CY2023Q1 | us-gaap |
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
|
usd | |
| CY2023Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
usd | |
| CY2023Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
usd | |
| CY2023Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
usd | |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
usd | |
| CY2024Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
usd | |
| CY2023Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
usd | |
| CY2023Q1 | ENVB |
Offering Costs Accrued Not Paid
OfferingCostsAccruedNotPaid
|
usd | |
| CY2023Q1 | ENVB |
Issuance Of Common Shares For Deferred Offering Costs
IssuanceOfCommonSharesForDeferredOfferingCosts
|
usd | |
| CY2024Q1 | ENVB |
Preferred Dividends Attributable To Redeemable Noncontrolling Interest
PreferredDividendsAttributableToRedeemableNoncontrollingInterest
|
usd | |
| CY2024Q1 | ENVB |
Accretion Of Embedded Derivative To Redemption Value
AccretionOfEmbeddedDerivativeToRedemptionValue
|
usd | |
| CY2024Q1 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
usd | |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
usd | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
shares | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
||
| CY2024Q1 | ENVB |
Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue
|
||
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
usd | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
usd | |
| CY2024Q1 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
168744 | usd |
| CY2023Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
210932 | usd |
| CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1933753 | usd |
| CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2948400 | usd |
| CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
458155 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1825792 | usd |
| CY2024Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
85409 | usd |
| CY2023Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
86486 | usd |
| CY2024Q1 | us-gaap |
Operating Costs And Expenses
OperatingCostsAndExpenses
|
2477317 | usd |
| CY2023Q1 | us-gaap |
Operating Costs And Expenses
OperatingCostsAndExpenses
|
4860678 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2477317 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4860678 | usd |
| CY2024Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-10039 | usd |
| CY2023Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-50657 | usd |
| CY2024Q1 | us-gaap |
Gain Loss On Investments
GainLossOnInvestments
|
11398 | usd |
| CY2023Q1 | us-gaap |
Gain Loss On Investments
GainLossOnInvestments
|
119505 | usd |
| CY2023Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
13000 | usd |
| CY2024Q1 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
696 | usd |
| CY2023Q1 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
-11 | usd |
| CY2024Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
22133 | usd |
| CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
183151 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-2455184 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-4677527 | usd |
| CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
1731 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2456915 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4677527 | usd |
| CY2023Q1 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
12329 | usd |
| CY2023Q1 | us-gaap |
Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
|
110991 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-2456915 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-4800847 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
17906 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
1968 | usd |
| CY2024Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-2439009 | usd |
| CY2023Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-4798879 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.61 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.61 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-2.31 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-2.31 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
4001456 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
4001456 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
2078271 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
2078271 | shares |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1956336 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
351488 | usd |
| CY2024Q1 | ENVB |
Common Stock Equity Distribution Costs
CommonStockEquityDistributionCosts
|
583713 | usd |
| CY2024Q1 | ENVB |
Stock Issued During Period Value Common Stock Sold Under Equity Distribution
StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
|
1808789 | usd |
| CY2024Q1 | ENVB |
Stock Issued During Period Value Issued Direct Offering Net Of Offering Cost
StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
|
322453 | usd |
| CY2024Q1 | ENVB |
Stock Issued During Period Value Exercise Of Inducement Warrants For Common Stock
StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock
|
2676980 | usd |
| CY2024Q1 | ENVB |
Net Offering Costs
NetOfferingCosts
|
12821 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
267679 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
|
1537140 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
17906 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2456915 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6481856 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14671924 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14671924 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
532835 | usd |
| CY2023Q1 | ENVB |
Preferred Dividends Attributable To Redeemable Noncontrolling Interest
PreferredDividendsAttributableToRedeemableNoncontrollingInterest
|
12329 | usd |
| CY2023Q1 | ENVB |
Accretion Of Embedded Derivative To Redemption Value
AccretionOfEmbeddedDerivativeToRedemptionValue
|
110991 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
1968 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4677527 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
10405880 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
10405880 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2456915 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4677527 | usd |
| CY2024Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-10039 | usd |
| CY2023Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-50657 | usd |
| CY2024Q1 | us-gaap |
Gain Loss On Investments
GainLossOnInvestments
|
11398 | usd |
| CY2023Q1 | us-gaap |
Gain Loss On Investments
GainLossOnInvestments
|
119505 | usd |
| CY2023Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
13000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
351488 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
532835 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
26847 | usd |
| CY2024Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
42188 | usd |
| CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
42188 | usd |
| CY2024Q1 | us-gaap |
Depreciation
Depreciation
|
43221 | usd |
| CY2023Q1 | us-gaap |
Depreciation
Depreciation
|
44298 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
759289 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1549354 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
202397 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
653712 | usd |
| CY2023Q1 | ENVB |
Increase Decrease In Rightofuse Operating Lease Asset And Obligation
IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation
|
26846 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2598347 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-5137009 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
5169 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-5169 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
|
1817640 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
2676980 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
2307707 | usd |
| CY2024Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
144058 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
6658269 | usd |
| CY2024Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
8137 | usd |
| CY2023Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-19893 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
4068059 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-5162071 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
2287977 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
17723884 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
6356036 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
12561813 | usd |
| CY2023Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
11 | usd |
| CY2024Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
24001 | usd |
| CY2024Q1 | ENVB |
Offering Costs Accrued Not Paid
OfferingCostsAccruedNotPaid
|
49249 | usd |
| CY2024Q1 | ENVB |
Issuance Of Common Shares For Deferred Offering Costs
IssuanceOfCommonSharesForDeferredOfferingCosts
|
322453 | usd |
| CY2023Q1 | ENVB |
Preferred Dividends Attributable To Redeemable Noncontrolling Interest
PreferredDividendsAttributableToRedeemableNoncontrollingInterest
|
12329 | usd |
| CY2023Q1 | ENVB |
Accretion Of Embedded Derivative To Redemption Value
AccretionOfEmbeddedDerivativeToRedemptionValue
|
110991 | usd |
| CY2024Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p id="xdx_808_eus-gaap--NatureOfOperations_zHDLLmKvCWQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1. <span id="xdx_827_zgZQ1iDtLYs2">BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nature of Operations</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric Biosciences, Inc. (“Enveric” or the “Company”) is a biotechnology company developing novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The head office of the Company is located in Naples, Florida. The Company has the following wholly-owned subsidiaries: Jay Pharma Inc. (“Jay Pharma”), 1306432 B.C. Ltd. (“HoldCo”), MagicMed Industries, Inc. (“MagicMed”), Enveric Canada Inc., and Enveric Therapeutics, Pty. Ltd. (“Enveric Therapeutics”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leveraging its unique discovery and development platform, the Psybrary™, Enveric has created a robust intellectual property portfolio of new chemical entities for specific mental health indications. Enveric’s lead program, the EVM201 Series, comprises next generation synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series – EB-002 (formerly, EB-373) – for the treatment of psychiatric disorders. Enveric is also advancing its second program, the EVM301 Series, expected to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the Company’s amalgamation with MagicMed completed in September 2021 (the “Amalgamation”), the Company has continued to pursue the development of MagicMed’s proprietary Psychedelic Derivatives library, the Psybrary™ which the Company believes will help to identify and develop the right drug candidates needed to address mental health challenges, including cancer-related distress. The Company synthesizes novel versions of classic psychedelics, such as psilocybin, DMT, mescaline and MDMA, using a mixture of chemistry and synthetic biology, resulting in the expansion of the Psybrary™, which includes 15 patent families with over a million potential variations and hundreds of synthesized molecules. Within the Psybrary™ the Company has three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). The Company is working to add novel psychedelic molecular compounds and derivatives (“Psychedelic Derivatives”) on a regular basis through its work at the Company’s labs in Calgary, Alberta, Canada, where the Company has a team of PhD scientists with expertise in synthetic biology and chemistry. To date the Company has created over 500 molecules that are housed in the Psybrary™.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company screens newly synthesized molecules in the Psybrary™ through PsyAI™, a proprietary artificial intelligence (“AI”) tool. Leveraging AI systems is expected to reduce the time and cost of pre-clinical, clinical, and commercial development. The Company believes it streamlines pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities, and pharmacological effects to help determine ideal drug candidates, tailored to each indication. Each of these molecules that the Company believes are patentable can then be further screened to see how changes to its makeup alter its effects in order to synthesize additional new molecules. New compounds of sufficient purity are undergoing pharmacological screening, including non-clinical (receptors/cell lines), preclinical (animal), and ultimately clinical (human) evaluations. The Company intends to utilize the Psybrary™ and the AI tool to categorize and characterize the Psybrary™ substituents to focus on bringing more psychedelics-inspired molecules from discovery to the clinical phase.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern, Liquidity and Other Uncertainties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has incurred a loss since inception resulting in an accumulated deficit of $<span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_di_c20240331_z9Fequr0c44i" title="Accumulated deficit">98,956,433</span> as of March 31, 2024 and further losses are anticipated in the development of its business. For the three months ended March 31, 2024, the Company has operating cash outflows of $<span id="xdx_904_eus-gaap--NetCashProvidedByUsedInOperatingActivities_di_c20240101__20240331_z4eATzng4E63" title="Net cash used in operating activities">2,598,347</span> and had a loss from operations of $<span id="xdx_905_eus-gaap--OperatingIncomeLoss_di_c20240101__20240331_zxVcubySKQqi" title="Loss from operations">2,477,317</span>. Since inception, being a research and development company, the Company has not yet generated revenue and the Company has incurred continuing losses from its operations. The Company’s operations have been funded principally through the issuance of equity. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In assessing the Company’s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate sufficient cash flow in the future to support its operating and capital expenditure commitments. At March 31, 2024, the Company had cash of $<span id="xdx_900_eus-gaap--Cash_iI_c20240331_zaQ9a99jDGV1" title="Cash">6,356,036</span> and working capital of $<span id="xdx_905_ecustom--WorkingCapital_iI_c20240331_zHVIqa1ohRUc" title="Working capital">5,860,884</span>. The Company’s current cash on hand is not sufficient enough to satisfy its operating cash needs for the 12 months from the filing of this Quarterly Report on Form 10-Q. These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the financial statements are issued. Management’s plan to alleviate the conditions that raise substantial doubt include raising additional working capital through public or private equity or debt financings or other sources, the Purchase Agreement with Lincoln Park (see Note 7 and 9), subject to registration, and may include additional collaborations with third parties as well as disciplined cash spending. Adequate additional financing may not be available to us on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital, the Company may be required to undertake cost-cutting measures including delaying or discontinuing certain operating activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of these factors, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date of the unaudited condensed consolidated financial statements are issued. The Company’s unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation Risks</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers the current inflationary trend existing in the North American economic environment reasonably likely to have a material unfavorable impact on results of continuing operations. Higher rates of price inflation, as compared to recent prior levels of price inflation, have caused a general increase in the cost of labor and materials. In addition, there is an increased risk of the Company experiencing labor shortages due to a potential inability to attract and retain human resources due to increased labor costs resulting from the current inflationary environment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq Notice</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 21, 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market stating that as of September 30, 2023, the Company did not meet the minimum of $<span id="xdx_90F_ecustom--MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_iI_c20231121_zke5eTsKVcOc" title="Minimum of stockholders equity required for continued listing pursuant to exchange">2,500,000</span> in stockholders’ equity required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1). On February 6, 2024, the Company received a letter from Nasdaq, granting the Company an extension to regain compliance with the minimum stockholders’ equity requirement by May 20, 2024. As of March 31, 2024, the Company is reporting stockholders’ equity of $<span id="xdx_901_eus-gaap--StockholdersEquity_iI_c20240331_zVOMIDfdh1j9" title="Stockholders equity">6,481,856</span>. Thus the Company believes that in filing this Quarterly Report on Form 10-Q for the period ended March 31, 2024, it will have regained and evidenced compliance with the Stockholders’ Equity Requirement by the required deadline. However, the Company’s compliance remains subject to review and analysis by Nasdaq.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-98956433 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2598347 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2477317 | usd |
| CY2024Q1 | us-gaap |
Cash
Cash
|
6356036 | usd |
| CY2024Q1 | ENVB |
Working Capital
WorkingCapital
|
5860884 | usd |
| CY2023Q4 | ENVB |
Minimum Of Stockholders Equity Required For Continued Listing Pursuant To Exchange
MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange
|
2500000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6481856 | usd |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p id="xdx_84B_eus-gaap--UseOfEstimates_zNZox531a3Sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zqQimCd8oZwl">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during the periods reported. By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of changes in such estimates in future periods could be significant. Significant areas requiring management’s estimates and assumptions include determining the fair value of transactions involving common stock, the valuation of warrants and preferred investment options, and the valuation of stock-based compensation and accruals associated with third party providers supporting research and development efforts. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> | |
| CY2023Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
149559 | usd |
| CY2024Q1 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
82353 | usd |
| CY2023Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
62036 | usd |
| CY2024Q1 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
395660 | usd |
| CY2023Q4 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
567603 | usd |
| CY2024Q1 | ENVB |
Prepaid Franchise Tax Receivable
PrepaidFranchiseTaxReceivable
|
58758 | usd |
| CY2024Q1 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zgbcYBSjsbf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zk66MPbeU601">Reclassification</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications have been made to the prior period’s unaudited condensed consolidated financial statements in order to conform to the current year presentation. In the prior year, the Company included certain investor related expenses were included within research and development on the unaudited condensed consolidated statements of operations. These expenses were reclassified to general and administrative expenses in the current year. This reclassification had no effect on the Company’s previously reported results of operations, changes in equity, or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | |
| CY2024Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zizUcqXqEeA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zhwDo0vIRC8f">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the federal depository insurance coverage of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20240331__srt--StatementGeographicalAxis__country--US_z1z8NvOgNHK7" title="Cash FDIC insured amount">250,000</span> in the United States and Australia and $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20240331__srt--StatementGeographicalAxis__country--CA_z8woIS2jP8Xj" title="Cash insured amount">100,000</span> in Canada. The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on such accounts. As of March 31, 2024, the Company had greater than $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20240331__srt--StatementGeographicalAxis__country--US_zgmKcMlHLIjh" title="Cash FDIC insured amount">250,000</span> at United States financial institutions, greater than $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20240331__srt--StatementGeographicalAxis__country--AU_zsp5npeTrGtg" title="Cash FDIC insured amount">250,000</span> at Australian financial institutions, and greater than $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20240331__srt--StatementGeographicalAxis__country--CA_ziltbh5S1h1g" title="Cash FDIC insured amount">100,000</span> at Canadian financial institutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> </p> | |
| CY2023Q4 | ENVB |
Prepaid Franchise Tax Receivable
PrepaidFranchiseTaxReceivable
|
79258 | usd |
| CY2024Q1 | ENVB |
Prepaid Research And Development Tax Incentive Receivable
PrepaidResearchAndDevelopmentTaxIncentiveReceivable
|
397022 | usd |
| CY2023Q4 | ENVB |
Prepaid Research And Development Tax Incentive Receivable
PrepaidResearchAndDevelopmentTaxIncentiveReceivable
|
145349 | usd |
| CY2024Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1872786 | usd |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1344136 | shares |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1927170 | shares |
| CY2024Q1 | ENVB |
Prepaid Research And Development
PrepaidResearchAndDevelopment
|
187701 | usd |
| CY2023Q4 | ENVB |
Prepaid Research And Development
PrepaidResearchAndDevelopment
|
46320 | usd |
| CY2024Q1 | us-gaap |
Prepaid Taxes
PrepaidTaxes
|
241577 | usd |
| CY2023Q4 | us-gaap |
Prepaid Taxes
PrepaidTaxes
|
243429 | usd |
| CY2024Q1 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
509715 | usd |
| CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1293554 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
210932 | usd |
| CY2024Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
42188 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
168744 | usd |
| CY2024Q1 | us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
0 | usd |
| CY2023Q1 | us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
0 | usd |
| CY2024Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
42188 | usd |
| CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
42188 | usd |
| CY2024Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
392170 | usd |
| CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
357711 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
452228 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
507377 | usd |
| CY2024Q1 | us-gaap |
Depreciation
Depreciation
|
43221 | usd |
| CY2023Q1 | us-gaap |
Depreciation
Depreciation
|
44298 | usd |
| CY2024Q1 | ENVB |
Accrued Product Development Cost
AccruedProductDevelopmentCost
|
70989 | usd |
| CY2023Q4 | ENVB |
Accrued Product Development Cost
AccruedProductDevelopmentCost
|
139981 | usd |
| CY2024Q1 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
112708 | usd |
| CY2023Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
8889 | usd |
| CY2024Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
172235 | usd |
| CY2023Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
584810 | usd |
| CY2024Q1 | ENVB |
Accrued Restructuring Costs
AccruedRestructuringCosts
|
113532 | usd |
| CY2023Q4 | ENVB |
Accrued Restructuring Costs
AccruedRestructuringCosts
|
301645 | usd |
| CY2023Q4 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
22318 | usd |
| CY2024Q1 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
18000 | usd |
| CY2023Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
18000 | usd |
| CY2024Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
487464 | usd |
| CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1075643 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
1817640 | usd |
| CY2024Q1 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
395660 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
255107 | usd |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
30329 | shares |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
57.17 | |
| CY2023Q4 | ENVB |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
|
77.22 | |
| CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P3Y4M24D | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
4493 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
44.25 | |
| CY2024Q1 | ENVB |
Share Based Compensation Arrangement By Share Based Payment Award Options Expired Forfeited Or Cancelled Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue
|
71.63 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
25836 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
59.42 | |
| CY2024Q1 | ENVB |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
|
78.20 | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P3Y1M6D | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
24586 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
62.29 | |
| CY2024Q1 | ENVB |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
|
82.04 | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P2Y9M18D | |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
358170 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
484749 | usd |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
358170 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
484749 | usd |
| CY2024Q1 | ENVB |
Prepaid Research And Development Tax Incentive Receivable
PrepaidResearchAndDevelopmentTaxIncentiveReceivable
|
397022 | usd |
| CY2023Q4 | ENVB |
Prepaid Research And Development Tax Incentive Receivable
PrepaidResearchAndDevelopmentTaxIncentiveReceivable
|
145349 | usd |
| CY2023Q2 | ENVB |
Reduction In Force Restructuring Percentage
ReductionInForceRestructuringPercentage
|
0.35 | pure |
| CY2023Q4 | us-gaap |
Restructuring And Related Cost Cost Incurred To Date1
RestructuringAndRelatedCostCostIncurredToDate1
|
301645 | usd |
| CY2024Q1 | us-gaap |
Restructuring Costs
RestructuringCosts
|
-188113 | usd |
| CY2024Q1 | us-gaap |
Restructuring And Related Cost Cost Incurred To Date1
RestructuringAndRelatedCostCostIncurredToDate1
|
113532 | usd |
